317 related articles for article (PubMed ID: 37633647)
21. The Small Molecules Targeting Ubiquitin-Proteasome System for Cancer Therapy.
Ao N; Chen Q; Liu G
Comb Chem High Throughput Screen; 2017; 20(5):403-413. PubMed ID: 28699494
[TBL] [Abstract][Full Text] [Related]
22. Hidden targets of ubiquitin proteasome system: To prevent diabetic nephropathy.
Goru SK; Kadakol A; Gaikwad AB
Pharmacol Res; 2017 Jun; 120():170-179. PubMed ID: 28363724
[TBL] [Abstract][Full Text] [Related]
23. Deubiquitinating enzyme inhibitors and their potential in cancer therapy.
Crosas B
Curr Cancer Drug Targets; 2014; 14(6):506-16. PubMed ID: 25088039
[TBL] [Abstract][Full Text] [Related]
24. Measuring activity in the ubiquitin-proteasome system: from large scale discoveries to single cells analysis.
Melvin AT; Woss GS; Park JH; Waters ML; Allbritton NL
Cell Biochem Biophys; 2013 Sep; 67(1):75-89. PubMed ID: 23686610
[TBL] [Abstract][Full Text] [Related]
25. The Tumor Suppressor Functions of Ubiquitin Ligase KPC1: From Cell-Cycle Control to NF-κB Regulator.
Gulei D; Drula R; Ghiaur G; Buzoianu AD; Kravtsova-Ivantsiv Y; Tomuleasa C; Ciechanover A
Cancer Res; 2023 Jun; 83(11):1762-1767. PubMed ID: 36880841
[TBL] [Abstract][Full Text] [Related]
26. The emerging role of Deubiquitinases (DUBs) in parasites: A foresight review.
Kumar P; Kumar P; Mandal D; Velayutham R
Front Cell Infect Microbiol; 2022; 12():985178. PubMed ID: 36237424
[TBL] [Abstract][Full Text] [Related]
27. [Metabolic pathways controlled by E3 ligases: an opportunity for therapeutic targeting].
Taillandier D
Biol Aujourdhui; 2021; 215(1-2):45-57. PubMed ID: 34397374
[TBL] [Abstract][Full Text] [Related]
28. The ubiquitin-proteasome system and cancer.
Devoy A; Soane T; Welchman R; Mayer RJ
Essays Biochem; 2005; 41():187-203. PubMed ID: 16250906
[TBL] [Abstract][Full Text] [Related]
29. Unstructured Biology of Proteins from Ubiquitin-Proteasome System: Roles in Cancer and Neurodegenerative Diseases.
Gadhave K; Kumar P; Kapuganti SK; Uversky VN; Giri R
Biomolecules; 2020 May; 10(5):. PubMed ID: 32455657
[TBL] [Abstract][Full Text] [Related]
30. Targeting ubiquitination for cancer therapies.
Morrow JK; Lin HK; Sun SC; Zhang S
Future Med Chem; 2015; 7(17):2333-50. PubMed ID: 26630263
[TBL] [Abstract][Full Text] [Related]
31. Assaying proteasomal degradation in a cell-free system in plants.
García-Cano E; Zaltsman A; Citovsky V
J Vis Exp; 2014 Mar; (85):. PubMed ID: 24747194
[TBL] [Abstract][Full Text] [Related]
32. [Research Progress of Ubiquitin Proteasome Inhibitors in Acute Myeloid Leukemia].
Xiao FN; Zhang MY; Zhou Y
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Oct; 44(5):868-875. PubMed ID: 36325785
[TBL] [Abstract][Full Text] [Related]
33. Role of E3 ubiquitin ligases and deubiquitinating enzymes in SARS-CoV-2 infection.
Zhao M; Zhang M; Yang Z; Zhou Z; Huang J; Zhao B
Front Cell Infect Microbiol; 2023; 13():1217383. PubMed ID: 37360529
[TBL] [Abstract][Full Text] [Related]
34. Ubiquitin Engineering for Interrogating the Ubiquitin-Proteasome System and Novel Therapeutic Strategies.
Tang JQ; Marchand MM; Veggiani G
Cells; 2023 Aug; 12(16):. PubMed ID: 37626927
[TBL] [Abstract][Full Text] [Related]
35. Estrogen and progesterone regulate p27kip1 levels via the ubiquitin-proteasome system: pathogenic and therapeutic implications for endometrial cancer.
Huang KT; Pavlides SC; Lecanda J; Blank SV; Mittal KR; Gold LI
PLoS One; 2012; 7(9):e46072. PubMed ID: 23029392
[TBL] [Abstract][Full Text] [Related]
36. Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition.
Patel K; Ahmed ZS; Huang X; Yang Q; Ekinci E; Neslund-Dudas CM; Mitra B; Elnady FA; Ahn YH; Yang H; Liu J; Dou QP
Future Med Chem; 2018 Sep; 10(17):2087-2108. PubMed ID: 30066579
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological Modulation of Ubiquitin-Proteasome Pathways in Oncogenic Signaling.
Sharma A; Khan H; Singh TG; Grewal AK; Najda A; Kawecka-Radomska M; Kamel M; Altyar AE; Abdel-Daim MM
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769401
[TBL] [Abstract][Full Text] [Related]
38. Ubiquitin proteasome system in immune regulation and therapeutics.
Bhat SA; Vasi Z; Adhikari R; Gudur A; Ali A; Jiang L; Ferguson R; Liang D; Kuchay S
Curr Opin Pharmacol; 2022 Dec; 67():102310. PubMed ID: 36288660
[TBL] [Abstract][Full Text] [Related]
39. Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin proteasome system: an insight into cullin-ring ubiquitin ligases.
Villeneuve NF; Lau A; Zhang DD
Antioxid Redox Signal; 2010 Dec; 13(11):1699-712. PubMed ID: 20486766
[TBL] [Abstract][Full Text] [Related]
40. Dysfunction of Avo3, an essential component of target of rapamycin complex 2, induces ubiquitin-proteasome-dependent downregulation of Avo2 in Saccharomyces cerevisiae.
Chen PK; Chang YJ; Chou YW; Chen MY
Biochem Biophys Res Commun; 2024 Jul; 717():150045. PubMed ID: 38718572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
